What's Happening?
Cleveland Clinic is preparing to open a new Neurological Institute building on its Main Campus in January 2027, which will feature a reengineered infusion suite called the advanced therapeutics space. This innovative unit is designed to integrate routine
patient care with complex clinical trial protocols, offering intensive outpatient nursing, specialized monitoring, and advanced research resources in a single location. The space will accommodate a range of neuropsychiatric therapies, including emerging cell-based treatments for autoimmune neurological disorders and neuromuscular conditions like myasthenia gravis. It will also be equipped for novel psychoactive and neuropsychiatric therapies, such as psychedelics, which require specialized settings for administration and monitoring. The facility includes 38 treatment bays, divided into semi-private and private rooms, to cater to diverse patient needs and treatment requirements, with modular design principles allowing for future reconfigurations.
Why It's Important?
This development positions Cleveland Clinic as a leader in early-phase clinical trials for neurological conditions, offering a streamlined environment for patients participating in complex therapeutic regimens. The integration of infusion and lab resources, advanced neuroimaging (including 7T MRI), and a neurological assessment center under one roof will facilitate proof-of-concept studies across various neurological subspecialties. The ability to handle 'last mile' cell product processing on-site and securely store controlled substances for neuropsychiatric therapies addresses critical logistical challenges in advanced treatment delivery. This model could set a new standard for healthcare facility design, fostering cross-disciplinary collaborations and accelerating the translation of research into clinical practice, ultimately benefiting patients with complex neurological and neuroimmunologic disorders by providing access to cutting-edge treatments.
What's Next?
The advanced therapeutics space is expected to open in January 2027 as part of the new Neurological Institute building. Cleveland Clinic researchers anticipate using this facility for ongoing early-phase clinical trials, including those evaluating CAR T-cell therapies for autoimmune neurological disorders and exploring new applications for investigational therapies. The space is also being prepared for the anticipated regulatory approval of psychedelic therapies, with plans to administer both short- and long-acting formulations. Furthermore, the unit's research-dedicated bays are slated for clinical trials involving ketamine for treatment-resistant depression. The operational template established by this advanced therapeutics space is intended to inform the development of a dedicated clinical trials unit within the new building, further integrating research infrastructure into daily clinical operations.
Beyond the Headlines
The design of the advanced therapeutics space reflects a forward-thinking approach to healthcare, moving beyond traditional infusion concepts to accommodate the evolving landscape of neurotherapeutic delivery. By creating an environment that supports both routine care and intricate clinical trials, Cleveland Clinic is addressing the ethical and practical challenges associated with administering highly specialized and often experimental treatments. The emphasis on patient comfort, sensory control, and secure handling of sensitive substances highlights a holistic view of patient care, particularly for those undergoing therapies with significant psychoactive effects. This integrated model could foster a culture of 'casual collisions' among specialists, potentially leading to new research projects and innovative treatment ideas, thereby shaping the future of neurological care and pushing the boundaries of medical science.
